electroCore, Inc.
NASDAQ:ECOR

Watchlist Manager
electroCore, Inc. Logo
electroCore, Inc.
NASDAQ:ECOR
Watchlist
Price: 16.0433 USD -1.33% Market Closed
Market Cap: 105.1m USD
Have any thoughts about
electroCore, Inc.?
Write Note

electroCore, Inc.
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

electroCore, Inc.
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
electroCore, Inc.
NASDAQ:ECOR
Total Liabilities & Equity
$21m
CAGR 3-Years
-24%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Total Liabilities & Equity
$57.3B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
16%
Boston Scientific Corp
NYSE:BSX
Total Liabilities & Equity
$38.1B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
9%
Stryker Corp
NYSE:SYK
Total Liabilities & Equity
$43.8B
CAGR 3-Years
9%
CAGR 5-Years
10%
CAGR 10-Years
10%
Abbott Laboratories
NYSE:ABT
Total Liabilities & Equity
$74.4B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
6%
Intuitive Surgical Inc
NASDAQ:ISRG
Total Liabilities & Equity
$17.7B
CAGR 3-Years
11%
CAGR 5-Years
14%
CAGR 10-Years
17%
No Stocks Found

electroCore, Inc.
Glance View

Market Cap
104.4m USD
Industry
Health Care

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).

ECOR Intrinsic Value
18.4922 USD
Undervaluation 13%
Intrinsic Value
Price

See Also

What is electroCore, Inc.'s Total Liabilities & Equity?
Total Liabilities & Equity
21m USD

Based on the financial report for Sep 30, 2024, electroCore, Inc.'s Total Liabilities & Equity amounts to 21m USD.

What is electroCore, Inc.'s Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
-14%

Over the last year, the Total Liabilities & Equity growth was 5%. The average annual Total Liabilities & Equity growth rates for electroCore, Inc. have been -24% over the past three years , -14% over the past five years .

Back to Top